Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?
We really appreciated the results presented by Jojima and colleagues [1]. Notably, researchers demonstrated that 12-week treatment with empagliflozin resulted in a significant increase in plasma levels of campesterol, while among statin non-users it also significantly decreased plasma levels of lathosterol [1]. The observed increase in campesterol levels significantly correlated with an increase in high-density lipoprotein cholesterol (HDL-C) levels [1].
Source: International Journal of Cardiology - Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas Tags: Letter to the Editor Source Type: research
More News: Cardiology | Cholesterol | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Statin Therapy